Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Environmental exposure chamber study of CEDARCURE Japanese cedar pollen sublingual tablets in Japanese cedar pollinosis
jRCT2031250165Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jul 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of japanese cedar pollen in allergic rhinitis (AR), sponsored by Torii Pharmaceutical. Primary endpoint: Change from baseline in TNSS120-180 on day 2 of Japanese cedar pollen exposure. Started Jul 2025; status: completed.
02
Drugs
japanese cedar pollen
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2031250165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250165.